BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaul S. Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True? Circulation. 2016;134:94-96. [PMID: 27400894 DOI: 10.1161/circulationaha.116.022537] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Singh AK, Singh R. Mortality outcome with different sodium-glucose co-transporter-2 inhibitors: Are they dissimilar? Endocr Pract 2022:S1530-891X(22)00558-4. [PMID: 35820610 DOI: 10.1016/j.eprac.2022.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Clark J, Muhlemann N, Natanegara F, Hartley A, Wenkert D, Wang F, Harrell FE Jr, Bray R; Medical Outreach Subteam of the Drug Information Association Bayesian Scientific Working Group. Why are not There More Bayesian Clinical Trials? Perceived Barriers and Educational Preferences Among Medical Researchers Involved in Drug Development. Ther Innov Regul Sci 2022. [PMID: 34978048 DOI: 10.1007/s43441-021-00357-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Suvarna VR. Sodium-glucose co-transporter-2 inhibitors: A cardiovascular outcome trial analysis. Perspect Clin Res 2021;12:4-8. [PMID: 33816202 DOI: 10.4103/picr.PICR_156_19] [Reference Citation Analysis]
4 Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;16:556-77. [PMID: 32855502 DOI: 10.1038/s41574-020-0392-2] [Cited by in Crossref: 90] [Cited by in F6Publishing: 95] [Article Influence: 30.0] [Reference Citation Analysis]
5 Stapff MP. Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes. World J Diabetes 2018; 9(12): 252-257 [PMID: 30588287 DOI: 10.4239/wjd.v9.i12.252] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
6 Halimi S. Inhibiteurs des SGLT2 : l’effet classe se confirme. Médecine des Maladies Métaboliques 2018;12:637-639. [DOI: 10.1016/s1957-2557(18)30171-8] [Reference Citation Analysis]
7 Kobalava ZD, Kiyakbaev GК. TYPE 2 DIABETES AND CARDIOVASCULAR COMPLICATIONS: IS IT POSSIBLE TO IMPROVE PROGNOSIS BY GLUCOSE LOWERING THERAPY? Russ J Cardiol 2018. [DOI: 10.15829/1560-4071-2018-8-79-91] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Bansilal S, Bhatt DL, Leiter LA, McGuire DK, Wilding JP, Gause-Nilsson IA, Langkilde AM, Johansson PA, Sabatine MS. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J 2018;200:83-9. [PMID: 29898853 DOI: 10.1016/j.ahj.2018.01.012] [Cited by in Crossref: 92] [Cited by in F6Publishing: 98] [Article Influence: 18.4] [Reference Citation Analysis]
9 Zhou H, Wang S, Zhu P, Hu S, Chen Y, Ren J. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol 2018;15:335-46. [PMID: 29306791 DOI: 10.1016/j.redox.2017.12.019] [Cited by in Crossref: 254] [Cited by in F6Publishing: 269] [Article Influence: 42.3] [Reference Citation Analysis]
10 Ghosal S. Cardio Vascular Outcomes Trials (CVOTs) with Anti-Hyperglycemic Agents: Demystifying Statistical Complexities. JDMDC 2017;4. [DOI: 10.15406/jdmdc.2017.04.00116] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
11 Singh AK, Singh R. Recent cardiovascular outcome trials of antidiabetic drugs: A comparative analysis. Indian J Endocrinol Metab 2017;21:4-10. [PMID: 28217490 DOI: 10.4103/2230-8210.196026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
12 Fitchett D. Editorial commentary: Anti-glycemic drugs and heart failure—A new era. Trends in Cardiovascular Medicine 2017;27:152-154. [DOI: 10.1016/j.tcm.2016.08.005] [Reference Citation Analysis]